No Data
No Data
Guggenheim Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $20
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
ACADIA Pharmaceuticals | 10-K: FY2024 Annual Report
Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference
Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews
ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ...